Carlos A Valenzuela

Dr. Carlos A Valenzuela

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2024 in Viruses
Verified
Journal Article
Open access
PDF file
CVCarlos A Valenzuela
Carlos A Valenzuela
SSSergio Saucedo
Sergio Saucedo
MLManuel Llano
Manuel Llano
Schlafen (SLFN) is a family of proteins upregulated by type I interferons with a regulatory role in translation. Intriguingly, SLFN14 associates with the ribosome and can degrade rRNA, tRNA, and mRNA in vitro, but a role in translation is still unknown. Ribosomes are important regulatory hubs during translation elongation of mRNAs rich in rare codons. Therefore, we evaluated the potential role of SLFN14 in the expression of mRNAs enriched in rare codons, using HIV-1 genes as a model. We found that, in a variety of cell types, including primary immune cells, SLFN14 regulates the expression of HIV-1 and non-viral genes based on their codon adaptation index, a measurement of the synonymous codon usage bias; consequently, SLFN14 inhibits the replication of HIV-1. The potent inhibitory effect of SLFN14 on the expression of the rare codon-rich transcript HIV-1 Gag was minimized by codon optimization. Mechanistically, we found that the endoribonuclease activity of SLFN14 is required, and that ribosomal RNA degradation is involved. Therefore, we propose that SLFN14 impairs the expression of HIV-1 transcripts rich in rare codons, in a catalytic-dependent manner.

16 June 2026 in Cancer Research
Verified
Journal Article
Open access
RAVI THAKURRAVI THAKUR
RAVI THAKUR
DWDi Wang
Di Wang
THTuo Hu
Tuo Hu
CHChunbo He
Chunbo He
JZJunzhang Zhao
Junzhang Zhao
PSPankaj Singh
Pankaj Singh
Pancreatic ductal adenocarcinoma (PDAC) is characterized by frequent KRAS mutations, which activate the MAPK pathway to promote PDAC progression. In this study, we explored metabolic vulnerabilities of PDAC by assessing initial metabolic reprogramming upon ERK inhibition using metabolomics, lipidomics, and isotope-tracing experiments. ERK inhibition enhanced lipid turnover and fatty acid (FA) oxidation while inhibiting glycolysis, glucose oxidation, and glutamine metabolism in PDAC cells. Moreover, lipophagy, but not cytosolic lipolysis, was responsible for the increased lipid turnover and FA oxidation upon ERK inhibition. Lipophagy and lipophagy-fueled FA oxidation were induced by increased nuclear translocation and activity of the transcription factor TFEB. Pharmacologic inhibition of FA oxidation in combination with KRASG12D/MEK/ERK inhibitors synergistically decreased the growth of PDAC cell lines and organoids. The combination decreased tumor burden and improved survival in orthotopic cell line and patient-derived xenograft PDAC models. Overall, this study provides mechanistic insights into the development of metabolic resistance to KRAS signaling inhibition and demonstrates that FA oxidation is a metabolic vulnerability following KRAS signaling inhibition that can be utilized as an effective therapeutic target to treat PDAC. Significance: Treating pancreatic cancer with inhibitors that target the KRAS pathway rewires metabolism by increasing lipophagy and fatty acid oxidation, which can be targeted to sensitize tumors to KRAS signaling inhibition. See related article by Delgado Herrera et al., p. XX .

1 January 1992 in MRS Proceedings
Verified
Journal Article
Closed access
PDF file
SYShoji Yamaguchi
Shoji Yamaguchi
CVCarlos A Valenzuela
Carlos A Valenzuela
RPRichard S. Potember
Richard S. Potember

15 July 2026
Verified
Other
Open access
RAVI THAKURRAVI THAKUR
RAVI THAKUR
DWDi Wang
Di Wang
THTuo Hu
Tuo Hu
CHChunbo He
Chunbo He
JZJunzhang Zhao
Junzhang Zhao
PSPankaj Singh
Pankaj Singh
ERK inhibition accelerated lipid turnover in pancreatic cancer cells.

15 July 2026
Verified
Other
Open access
RAVI THAKURRAVI THAKUR
RAVI THAKUR
DWDi Wang
Di Wang
THTuo Hu
Tuo Hu
CHChunbo He
Chunbo He
JZJunzhang Zhao
Junzhang Zhao
PSPankaj Singh
Pankaj Singh
Pancreatic ductal adenocarcinoma (PDAC) is characterized by frequent KRAS mutations, which activate the MAPK pathway to promote PDAC progression. In this study, we explored metabolic vulnerabilities of PDAC by assessing initial metabolic reprogramming upon ERK inhibition using metabolomics, lipidomics, and isotope-tracing experiments. ERK inhibition enhanced lipid turnover and fatty acid (FA) oxidation while inhibiting glycolysis, glucose oxidation, and glutamine metabolism in PDAC cells. Moreover, lipophagy, but not cytosolic lipolysis, was responsible for the increased lipid turnover and FA oxidation upon ERK inhibition. Lipophagy and lipophagy-fueled FA oxidation were induced by increased nuclear translocation and activity of the transcription factor TFEB. Pharmacologic inhibition of FA oxidation in combination with KRASG12D/MEK/ERK inhibitors synergistically decreased the growth of PDAC cell lines and organoids. The combination decreased tumor burden and improved survival in orthotopic cell line and patient-derived xenograft PDAC models. Overall, this study provides mechanistic insights into the development of metabolic resistance to KRAS signaling inhibition and demonstrates that FA oxidation is a metabolic vulnerability following KRAS signaling inhibition that can be utilized as an effective therapeutic target to treat PDAC.Significance:Treating pancreatic cancer with inhibitors that target the KRAS pathway rewires metabolism by increasing lipophagy and fatty acid oxidation, which can be targeted to sensitize tumors to KRAS signaling inhibition.See related commentary by Delgado Herrera and Ferrer, p. 3374

15 July 2026
Verified
Other
Open access
RAVI THAKURRAVI THAKUR
RAVI THAKUR
DWDi Wang
Di Wang
THTuo Hu
Tuo Hu
CHChunbo He
Chunbo He
JZJunzhang Zhao
Junzhang Zhao
PSPankaj Singh
Pankaj Singh
Cell growth and lipidomic changes upon ERK inhibition in combination with inhibition of fatty acid oxidation.